Advertisement

Topics

Allergan's Schizophrenia Treatment Receives OK From FDA

08:42 EST 13 Nov 2017 | Pharmaceutical Processing

Label expansion includes new data showing long-term Vraylar therapy delayed time to relapse compared to placebo over the course of up to 72 weeks.
Contributed Author: 
Allergan plc

Original Article: Allergan's Schizophrenia Treatment Receives OK From FDA

NEXT ARTICLE

More From BioPortfolio on "Allergan's Schizophrenia Treatment Receives OK From FDA"

Advertisement
Quick Search
Advertisement
Advertisement